Log In
BCIQ
Print this Print this
 

Xclair

  Manage Alerts
Collapse Summary General Information
Company Hexim Pharmaceuticals Inc.
DescriptionCream in a hydrolipidic base
Molecular Target Not applicable
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDermatitis
Indication DetailsManage and relieve symptoms of radiation-induced dermatitis
Regulatory Designation
PartnerMenarini Group;
Quintiles Transnational Holdings Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$1.8M

$1.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today